DR. JOHN K CAMORIANO M.D. NPI 1396723425

NPI Details

DR. John K Camoriano, M.D. is a hematology and oncology internal medicine in Scottsdale, AZ with 44 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. John K Camoriano, M.D. NPI is 1396723425. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF NEBRASKA COLLEGE OF MEDICINE
Graduation Year:1982

The provider's business location address is:

13400 E SHEA BLVD
SCOTTSDALE, AZ
ZIP 85259-404
Phone: (480) 301-8000

The NPI 1396723425 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Telephone or internet assessment with written report by consulting physician, 5 minutes or more (HCPCS:99451)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 1/9/2006 and was last updated on 9/10/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: